These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Baldo B; Paganetti P; Grueninger S; Marcellin D; Kaltenbach LS; Lo DC; Semmelroth M; Zivanovic A; Abramowski D; Smith D; Lotz GP; Bates GP; Weiss A Chem Biol; 2012 Feb; 19(2):264-75. PubMed ID: 22365609 [TBL] [Abstract][Full Text] [Related]
43. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Li H; Li SH; Cheng AL; Mangiarini L; Bates GP; Li XJ Hum Mol Genet; 1999 Jul; 8(7):1227-36. PubMed ID: 10369868 [TBL] [Abstract][Full Text] [Related]
44. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890 [TBL] [Abstract][Full Text] [Related]
45. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Waelter S; Boeddrich A; Lurz R; Scherzinger E; Lueder G; Lehrach H; Wanker EE Mol Biol Cell; 2001 May; 12(5):1393-407. PubMed ID: 11359930 [TBL] [Abstract][Full Text] [Related]
47. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Hackam AS; Hodgson JG; Singaraja R; Zhang T; Gan L; Gutekunst CA; Hersch SM; Hayden MR Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1047-55. PubMed ID: 10434304 [TBL] [Abstract][Full Text] [Related]
48. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706 [TBL] [Abstract][Full Text] [Related]
49. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Lee WC; Yoshihara M; Littleton JT Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3224-9. PubMed ID: 14978262 [TBL] [Abstract][Full Text] [Related]
50. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536 [TBL] [Abstract][Full Text] [Related]
51. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146 [TBL] [Abstract][Full Text] [Related]
52. Inactivation of Apaf1 reduces the formation of mutant huntingtin-dependent aggregates and cell death. Sancho M; Herrera AE; Orzáez M; Pérez-Payá E Neuroscience; 2014 Mar; 262():83-91. PubMed ID: 24412373 [TBL] [Abstract][Full Text] [Related]
53. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Martindale D; Hackam A; Wieczorek A; Ellerby L; Wellington C; McCutcheon K; Singaraja R; Kazemi-Esfarjani P; Devon R; Kim SU; Bredesen DE; Tufaro F; Hayden MR Nat Genet; 1998 Feb; 18(2):150-4. PubMed ID: 9462744 [TBL] [Abstract][Full Text] [Related]
54. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678 [TBL] [Abstract][Full Text] [Related]
55. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease. Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509 [TBL] [Abstract][Full Text] [Related]
56. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Li SH; Li XJ Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808 [TBL] [Abstract][Full Text] [Related]
58. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804 [TBL] [Abstract][Full Text] [Related]
59. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Nucifora FC; Sasaki M; Peters MF; Huang H; Cooper JK; Yamada M; Takahashi H; Tsuji S; Troncoso J; Dawson VL; Dawson TM; Ross CA Science; 2001 Mar; 291(5512):2423-8. PubMed ID: 11264541 [TBL] [Abstract][Full Text] [Related]
60. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Truant R; Atwal RS; Burtnik A Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]